Bellicum Pharmaceuticals, Inc. (BLCM) Upgraded to Sell by ValuEngine
ValuEngine upgraded shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) from a strong sell rating to a sell rating in a report released on Monday.
Other equities analysts have also issued research reports about the company. Cantor Fitzgerald set a $32.00 price objective on Bellicum Pharmaceuticals and gave the company a buy rating in a research note on Saturday, June 24th. Ladenburg Thalmann Financial Services set a $31.00 price target on Bellicum Pharmaceuticals and gave the company a buy rating in a research note on Saturday, June 24th. Raymond James Financial, Inc. restated a buy rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Jefferies Group LLC restated a buy rating and issued a $16.00 price target on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. Finally, BidaskClub upgraded Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, August 25th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Bellicum Pharmaceuticals has an average rating of Hold and an average price target of $26.20.
Bellicum Pharmaceuticals (NASDAQ:BLCM) opened at 12.73 on Monday. Bellicum Pharmaceuticals has a 1-year low of $7.41 and a 1-year high of $23.11. The firm’s market cap is $422.97 million. The firm has a 50-day moving average of $9.55 and a 200 day moving average of $11.70.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same period in the previous year, the business posted ($0.61) EPS. On average, analysts predict that Bellicum Pharmaceuticals will post ($3.02) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Bellicum Pharmaceuticals, Inc. (BLCM) Upgraded to Sell by ValuEngine” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/19/bellicum-pharmaceuticals-inc-blcm-upgraded-to-sell-by-valuengine.html.
In related news, insider David M. Spencer sold 10,000 shares of Bellicum Pharmaceuticals stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $11.54, for a total value of $115,400.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Ken Moseley sold 13,823 shares of Bellicum Pharmaceuticals stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $12.26, for a total value of $169,469.98. Following the completion of the sale, the vice president now owns 14,314 shares in the company, valued at $175,489.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 24,260 shares of company stock worth $290,048. 23.30% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the stock. Knott David M acquired a new stake in Bellicum Pharmaceuticals in the 1st quarter worth about $131,000. Monashee Investment Management LLC acquired a new stake in Bellicum Pharmaceuticals in the 1st quarter worth about $1,974,000. Sphera Funds Management LTD. boosted its holdings in Bellicum Pharmaceuticals by 25.0% in the 2nd quarter. Sphera Funds Management LTD. now owns 250,000 shares of the biopharmaceutical company’s stock worth $2,920,000 after buying an additional 50,000 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Bellicum Pharmaceuticals in the 1st quarter worth about $277,000. Finally, LMR Partners LLP acquired a new stake in Bellicum Pharmaceuticals in the 1st quarter worth about $3,339,000. Institutional investors own 55.73% of the company’s stock.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.